A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017)

References

• Mulvihill MM, Nomura DK. Therapeutic potential of monoacylglycerol lipase inhibitors. Life Sci. 2013;92:492–497.
   PubMed Web of Science ®Google Scholar
• Nomura DK, Long JZ, Niessen S, et al. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell. 2010;140:49–61.
   PubMed Web of Science ®Google Scholar
• Guindon J, Guijarro A, Piomelli D, et al. Peripheral antinociceptive effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain. Br J Pharmacol. 2011;163:1464–1478.
   PubMed Web of Science ®Google Scholar
• Kinsey SG, O’Neal ST, Long JZ, et al. Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay. Pharmacol Biochem Behav. 2011;98:21–27.
   PubMed Web of Science ®Google Scholar
• Chen R, Zhang J, Wu Y, et al. Monoacylglycerol lipase is a therapeutic target for Alzheimer’s disease. Cell Rep. 2012;2:1329–1339.
   PubMed Web of Science ®Google Scholar
• Alhouayek M, Masquelier J, Muccioli GG. Controlling 2-arachidonoylglycerol metabolism as an anti-inflammatory strategy. Drug Discov Today. 2014;19(3):295–304.
   PubMed Web of Science ®Google Scholar
• Kinsey SG, Wise LE, Ramesh D, et al. Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects. J Pharmacol Exp Ther. 2013;345:492–501.
   PubMed Web of Science ®Google Scholar
• Alhouayek M, Lambert DM, Delzenne NM, et al. Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation. Faseb J. 2011;25:2711–2721.
   PubMed Web of Science ®Google Scholar
• Ye L, Zhang B, Seviour EG, et al. Monoacylglycerol lipase (MAGL) knockdown inhibits tumor cells growth in colorectal cancer. Cancer Lett. 2011;307:6–17.
   PubMed Web of Science ®Google Scholar
• Nomura DK, Lombardi DP, Chang JW, et al. Monoacylglycerol lipase exerts dual control over endocannabinoid and fatty acid pathways to support prostate cancer. Chem Biol. 2011;18:846–856.
   PubMed Web of Science ®Google Scholar
• Kopp F, Komatsu T, Nomura DK, et al. The glycerophospho metabolome and its influence on amino acid homeostasis revealed by brain metabolomics of GDE1(-/-) mice. Chem Biol. 2010;17:831–840.
   PubMed Web of Science ®Google Scholar
• Labar G, Wouters J, Lambert DM. A review on the monoacylglycerol lipase: at the interface between fat and endocannabinoid signalling. Curr Med Chem. 2010;17:2588–2607.
   PubMed Web of Science ®Google Scholar
• King AR, Lodola A, Carmi C, et al. A critical cysteine residue in monoacylglycerol lipase is targeted by a new class of isothiazolinone-based enzyme inhibitors. Br J Pharmacol. 2009;157:974–983.
   PubMed Web of Science ®Google Scholar
• Granchi C, Rizzolio F, Bordoni V, et al. 4-Aryliden-2-methyloxazol-5(4H)-one as a new scaffold for selective reversible MAGL inhibitors. J Enzym Inhib Med Chem. 2016;31:137–146.
   PubMed Web of Science ®Google Scholar
• Hernandez-Torres G, Cipriano M, Heden E, et al. A reversible and selective inhibitor of monoacylglycerol lipase ameliorates multiple sclerosis. Angew Chem Int Ed Engl. 2014;53:13765–13770.
   PubMed Web of Science ®Google Scholar
• Tuccinardi T, Granchi C, Rizzolio F, et al. Identification and characterization of a new reversible MAGL inhibitor. Bioorg Med Chem. 2014;22:3285–3291.
   PubMed Web of Science ®Google Scholar
• Granchi C, Rizzolio F, Palazzolo S, et al. Structural Optimization of 4-Chlorobenzoylpiperidine Derivatives for the Development of Potent, Reversible, and Selective Monoacylglycerol Lipase (MAGL) Inhibitors. J Med Chem. 2016;59:10299–10314.
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceutica NV Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacyglycerol lipase inhibitors. WO2010124122. 2010.
   Google Scholar
• Janssen Pharmaceutica NV Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacyglycerol lipase inhibitors. WO2010124121. 2010.
   Google Scholar
• Schalk-Hihi C, Schubert C, Alexander R, et al. Crystal structure of a soluble form of human monoglyceride lipase in complex with an inhibitor at 1.35 A resolution. Prot Science. 2011;20:670–683.
   Web of Science ®Google Scholar
• Janssen Pharmaceutica NV Monoacylglycerol lipase inhibitors for the treatment of metabolic disease and related disorders. WO2013049289. 2013.
   Google Scholar
• Taschler U, Radner FP, Heier C, et al. Monoglyceride lipase deficiency in mice impairs lipolysis and attenuates diet-induced insulin resistance. J Biol Chem. 2011;286:17467–17477.
   PubMed Web of Science ®Google Scholar
• Chon SH, Douglass JD, Zhou YX, et al. Over-expression of monoacylglycerol lipase (MGL) in small intestine alters endocannabinoid levels and whole body energy balance, resulting in obesity. PLoS One. 2012;7:e43962.
   PubMed Web of Science ®Google Scholar
• Douglass JD, Zhou YX, Wu A, et al. Global deletion of MGL in mice delays lipid absorption and alters energy homeostasis and diet-induced obesity. J Lipid Res. 2015;56:1153–1171.
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceutica NV Monoacylglycerol lipase inhibitors for the treatment of metabolic disease and related disorders. WO2013049293. 2013.
   Google Scholar
• Connolly PJ, Bian H, Li X, et al. Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors. US20130102584. 2013.
   Google Scholar
• INSERM, Université Paris Diderot, Centre National de la Recherche Scientifique. Methods and pharmaceutical compositions for the treatment of fibrosis. WO2016046130. 2016.
   Google Scholar
• Niphakis MJ, Cognetta AB 3rd, Chang JW, et al. Evaluation of NHS carbamates as a potent and selective class of endocannabinoid hydrolase inhibitors. ACS Chem Neurosci. 2013;4:1322–1332.
   PubMed Web of Science ®Google Scholar
• Long JZ, Li W, Booker L, et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol. 2009;5:37–44.
   PubMed Web of Science ®Google Scholar
• Takeda Pharmaceutical. 4-(Piperazin-1-yl)-pyrrolidin-2-one compounds as monoacyglycerol lipase (MAGL) inhibitors. WO2015099196. 2015.
   Google Scholar
• Pihlaja R, Takkinen J, Eskola O, et al. Monoacylglycerol lipase inhibitor JZL184 reduces neuroinflammatory response in APdE9 mice and in adult mouse glial cells. J Neuroinflammation. 2015;12:81.
   PubMed Web of Science ®Google Scholar
• Piro JR, Benjamin DI, Duerr JM, et al. A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer’s disease. Cell Rep. 2012;1:617–623.
   PubMed Web of Science ®Google Scholar
• Pasquarelli N, Engelskirchen M, Hanselmann J, et al. Evaluation of monoacylglycerol lipase as a therapeutic target in a transgenic mouse model of ALS. Neuropharmacology. 2017;124:157–169.
   PubMed Web of Science ®Google Scholar
• Pasquarelli N, Porazik C, Bayer H, et al. Contrasting effects of selective MAGL and FAAH inhibition on dopamine depletion and GDNF expression in a chronic MPTP mouse model of Parkinson’s disease. Neurochem Int. 2017;110:14–24.
   PubMed Web of Science ®Google Scholar
• Zhang J, Teng Z, Song Y, et al. Inhibition of monoacylglycerol lipase prevents chronic traumatic encephalopathy-like neuropathology in a mouse model of repetitive mild closed head injury. J Cereb Blood Flow Metab. 2015;35:443–453.
   PubMed Web of Science ®Google Scholar
• Bedse G, Hartley ND, Neale E, et al. Functional redundancy between canonical endocannabinoid signaling systems in the modulation of anxiety. Biol Psychiatry. 2017;82:488–499.
   PubMed Web of Science ®Google Scholar
• Woodhams SG, Chapman V, Finn DP, et al. The cannabinoid system and pain. Neuropharmacology. 2017;124:105–120.
   PubMed Web of Science ®Google Scholar
• Von Rüden EL, Bogdanovic RM, Wotjak CT, et al. Inhibition of monoacylglycerol lipase mediates a cannabinoid 1-receptor dependent delay of kindling progression in mice. Neurobiol Dis. 2015;77:238–245.
   PubMed Web of Science ®Google Scholar
• Abide Therapeutics Inc. Carbamate compounds and of making and using same. WO2013103973. 2013.
   Google Scholar
• Abide Therapeutics Inc. Piperazine carbamates and methods of making and using same. WO2016149401. 2016.
   Google Scholar
• Abide Therapeutics Inc. Methods of treating inflammation or neuropathic pain. WO2016183097. 2016.
   Google Scholar
• Abide Therapeutics Inc. Carbamate compounds and of making and using same. WO2013142307. 2013.
   Google Scholar
• Pfizer Inc. 1,1,1-Trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors. WO2017021805 (2017).
   Google Scholar
• Abide Therapeutics Inc. Pyrrolo-Pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof. WO2015003002. 2015.
   Google Scholar
• Northeastern University. Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof. WO2016014975. 2016.
   Google Scholar
• Long JZ, Nomura DK, Vann RE, et al. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc Natl Acad Sci U S A. 2009;106:20270–20275.
   PubMed Web of Science ®Google Scholar
• Abide Therapeutics Inc. Pyrazole compounds and methods of making and using same. WO2015179559. 2015.
   Google Scholar
• Abide Therapeutics Inc. Pyrazole compounds and methods of making and using same. WO2017087854. 2017.
   Google Scholar
• Abide Therapeutics Inc. Pyrazole compounds and methods of making and using same. WO2017087863. 2017.
   Google Scholar
• Gmbh & Co. KG. Novel 1,3-benzoxazol-2(3H)-ones and their use as medicaments and cosmetics. WO2013174508. 2013.
   Google Scholar
• Northeastern University. Novel lipase inhibitors, reporter substrates and uses thereof. WO2013177492. 2013.
   Google Scholar
• Takeda Pharmaceutical Company Limited. Heterocyclic compound. WO2016158956. 2016.
   Google Scholar
• Infinity Pharmaceuticals Inc. Inhibitors of monoacyglycerol lipase and methods of their use. WO2013049332. 2013.
   Google Scholar
• Matuszak N, Muccioli GG, Labar G, et al. Synthesis and in vitro evaluation of N-substituted maleimide derivatives as selective monoglyceride lipase inhibitors. J Med Chem. 2009;52:7410–7420.
   PubMed Web of Science ®Google Scholar
• Schlosburg JE, Blankman JL, Long JZ, et al. Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci. 2010;13:1113–1119.
   PubMed Web of Science ®Google Scholar
• Granchi C, Caligiuri I, Bertelli E, et al. Development of terphenyl-2-methyloxazol-5(4H)-one derivatives as selective reversible MAGL inhibitors. J Enzym Inhib Med Chem. 2017;32:1240-1252.
   Web of Science ®Google Scholar
• Gowlugari S, De Falco J, Nguyen MT, et al. Discovery of potent, non-carbonyl inhibitors of fatty acid amide hydrolase (FAAH). Med Chem Commun. 2012;3:1258–1263.
   Web of Science ®Google Scholar
• Chobanian HR, Guo Y, Liu P, et al. Discovery of MK-4409, a novel oxazole FAAH Inhibitor for the treatment of inflammatory and neuropathic pain. ACS Med Chem Lett. 2014;5:717–721.
   PubMed Web of Science ®Google Scholar
• Lord CC, Thomas G, Brown JM. Mammalian alpha beta hydrolase domain (ABHD) proteins: lipid metabolizing enzymes at the interface of cell signaling and energy metabolism. Biochim Biophys Acta. 2013;1831:792–802.
   PubMed Web of Science ®Google Scholar
• Navia-Paldanius D, Savinainen JR, Laitinen JT. Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12). J Lipid Res. 2012;53:2413–2424.
   PubMed Web of Science ®Google Scholar
• Leung D, Hardouin C, Boger DL, et al. Discovering potent and selective reversible inhibitors of enzymes in complex proteomes. Nat Biotechnol. 2003;21:687–691.
   PubMed Web of Science ®Google Scholar
• [ cited 2017 Feb 08]. https://www.clinicaltrials.gov/ct2/search.
   Google Scholar